The predictive factors for the response to platinum/paclitaxel based first-line adjuvant chemotherapy in advanced ovarian cancer

National Medical Journal of China

Volumn 87, Issue 17, 2007, Pages 1187-1189

  Wei, Feng Hua ^a   Zhao, Xiao Dong ^b   Zhang, Yi ^b   He, Shu Rong ^b   Yang, Li ^b  

^a BEIJING HOSPITAL   (China)

^b NONE

Author keywords

Chemotherapy; Ovarian neoplasms; Paclitaxel; Prediction

Indexed keywords

GLYCOPROTEIN P; PACLITAXEL; PLATINUM COMPLEX; PROTEIN P53;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; ARTICLE; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SIZE; CLINICAL ARTICLE; CLINICAL FEATURE; CORRELATION ANALYSIS; DRUG CHOICE; DRUG EFFICACY; DRUG RESPONSE; FACTORIAL ANALYSIS; FEMALE; GENETIC CODE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OUTCOME ASSESSMENT; OVARIECTOMY; OVARY CANCER; PREDICTION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RECURRENCE RISK; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OVARIAN NEOPLASMS; OVARY; P-GLYCOPROTEIN; PACLITAXEL; PLATINUM; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34447555984     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Chinese source.
2. Chinese source.
3. Rustin GJS, Nelstrop AE, Bentzen SM, et al. Use of tumor markers in monitoring the course of ovarian cancer. Ann Oncol, 1999, 10 Suppl 1:21-27.
4. Chi DS, Liao JB, Leon LF, et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol, 2001, 82: 532-537.
5. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol, 2002, 20: 1248-1259.
6. Van der Burg MEL, van Lent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med, 1995, 332: 629-634.
7. Penson RT, Oliva E, Skates SJ, et al. Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol Oncol, 2004, 93: 98-106.
8. Chinese source.
9. Chinese source.
10. Chinese source.
11. Buttitta F, Marchetti A, Gadducci A, et al. p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br J Cancer, 1997, 75: 230-235.
12. Lavarino C, Pilotti S, Oggionni M, et al. p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. J Clin Oncol, 2000, 18: 3936-3945.